IO Biotech Past Earnings Performance
Past criteria checks 0/6
IO Biotech's earnings have been declining at an average annual rate of -26%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-26.0%
Earnings growth rate
72.8%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -124.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate
Jun 12
We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully
Feb 10We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully
Jun 15We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully
Jan 20IO Biotech names new CFO
Oct 13We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate
Sep 27IO Biotech GAAP EPS of -$0.64
Aug 11We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate
Jun 14We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully
Feb 25Revenue & Expenses Breakdown
How IO Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -90 | 24 | 72 |
| 30 Jun 24 | 0 | -88 | 24 | 70 |
| 31 Mar 24 | 0 | -88 | 23 | 70 |
| 31 Dec 23 | 0 | -86 | 24 | 68 |
| 30 Sep 23 | 0 | -80 | 23 | 60 |
| 30 Jun 23 | 0 | -74 | 23 | 53 |
| 31 Mar 23 | 0 | -71 | 24 | 49 |
| 31 Dec 22 | 0 | -71 | 24 | 47 |
| 30 Sep 22 | 0 | -74 | 23 | 49 |
| 30 Jun 22 | 0 | -65 | 21 | 43 |
| 31 Mar 22 | 0 | -87 | 17 | 38 |
| 31 Dec 21 | 0 | -75 | 11 | 30 |
| 30 Sep 21 | 0 | -56 | 6 | 16 |
| 30 Jun 21 | 0 | -54 | 4 | 15 |
| 31 Mar 21 | 0 | -17 | 2 | 10 |
| 31 Dec 20 | 0 | -15 | 2 | 8 |
Quality Earnings: IOBT is currently unprofitable.
Growing Profit Margin: IOBT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IOBT is unprofitable, and losses have increased over the past 5 years at a rate of 26% per year.
Accelerating Growth: Unable to compare IOBT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IOBT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: IOBT has a negative Return on Equity (-124.5%), as it is currently unprofitable.